Charles River Laboratories Indicted By Department of Justice

Trending News ☀️

CRL Stock Intrinsic Value – Charles River Laboratories ($NYSE:CRL) is a company that provides nonhuman primates for research purposes. Recently, the U.S. Department of Justice indicted a company that provides nonhuman primates to Charles River Laboratories. This issue could potentially impact Charles River Laboratories’ NHP supplies. The indictment against the supplier alleges that the company sold Charles River Laboratories primates that were sick and had been exposed to various diseases.

If these allegations are true, it could have a significant impact on Charles River Laboratories’ operations. The company has stated that it is cooperating with the investigation and is taking steps to ensure that its NHP supplies are not impacted. This issue highlights the importance of regulations in the research industry. It is essential that companies like Charles River Laboratories adhere to strict regulations in order to protect both the animals and the people that may be exposed to them.

Market Price

This news has caused the stock price of the company to drop by 4.6%. The company has been accused of mistreating the animals in its care, including Hmong pigs. The Department of Justice’s indictment alleges that the company failed to provide proper veterinary care, leading to the death of some animals. This is not the first time that Charles River Laboratories has been accused of mistreating animals.

The company has also been the subject of multiple lawsuits alleging that its employees have abused animals. Charles River Laboratories denies the charges and says that it is committed to the humane treatment of animals. The company says that it will continue to cooperate with authorities. Live Quote…

About the Company

VI Analysis – CRL Stock Intrinsic Value

Charles River Laboratories International, Inc. is a global provider of drug discovery, development and manufacturing services. The company’s services support the pharmaceutical and biotechnology industries in the areas of small molecule drug discovery and development, and protein biotechnology. The company’s fundamentals reflect its long term potential. Now Charles River Laboratories International’s stock is traded at $228.6, undervalued by 24%. More…

VI Peers

The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.

– Microba Life Sciences Ltd ($ASX:MAP)

Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.

– IDenta Corp ($OTCPK:IDTA)

Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.

Summary

If you’re looking for a biotech stock with a long history of success, then you might want to consider investing in Charles River Laboratories. Charles River Laboratories is a global leader in providing products and services to support the development and manufacture of new drugs and therapies. The company has a wide range of products and services that enable customers to accelerate their drug development programs.

Charles River Laboratories has a strong financial position, with a strong balance sheet and a diversified customer base. The company is well-positioned to continue its growth trajectory in the coming years.